Correlation Engine 2.0
Clear Search sequence regions


  • allele (3)
  • case control study (2)
  • CD14 (2)
  • CD16 (3)
  • DRD4 (3)
  • drd4 protein, human (1)
  • dyslipidemia (2)
  • gene (4)
  • humans (1)
  • lipid (4)
  • monocyte (2)
  • patients (5)
  • protein human (1)
  • receptors (4)
  • Sizes of these terms reflect their relevance to your search.

    Because dopaminergic signaling pathways are one of the regulators of autoimmunity, we hypothesize that the -521C>T DRD4 gene polymorphism may associate with the risk of diabetes mellitus type 1 (DM1) and its comorbidities. In this case-control study, we have examined 300 patients with DM1 in comparison to 300 healthy age-matched controls. Utilizing the amplification refractory mutation system-polymerase chain reaction method, we have analyzed the -521C>T polymorphism of dopamine D4 receptor-encoding gene. Obtained results have been evaluated according to diabetes comorbidities, inflammatory markers, CD14++CD16-, and CD14+CD16+ monocyte subsets as well as lipid profile. The key results of our study are as follows: (1) CC genotype and C allele are associated with a reduced risk of DM1 development (OR = 0.593, p = 0.005 and OR = 0.725, p = 0.003, respectively), whereas TT genotype and T allele are associated with a higher risk of DM1 (OR = 1.408, p = 0.04 and OR = 1.380, p = 0.003, respectively); (2) CC genotype is associated with an increased risk of dyslipidemia and retinopathy in diabetic patients (OR = 2.376, p = 0.001 and OR = 2.111, p = 0.01, respectively); (3) CC genotype and C allele carriers had the highest frequency of pro-inflammatory CD16+ monocytes (p = 2*10-4 and 0.04, respectively); (4) the DRD4 -521C>T polymorphism modifies the inflammatory status as well as lipid profile in DM1 patients. Our data imply that the dopaminergic signaling pathways may play an important role in the etiology of DM1 as well as its comorbidities and will provide a new insight into the DM1 risk management. The -521C>T DRD4 gene polymorphism could be considered a genetic marker to predict susceptibility to DM1 as well as retinopathy and dyslipidemia progress in patients with already established disease. © 2023 The Author(s). Published by S. Karger AG, Basel.

    Citation

    Bartosz Słomiński, Maria Skrzypkowska, Małgorzata Myśliwiec, Piotr Trzonkowski. Variation in the Dopamine-4-Receptor Gene in Patients with Type 1 Diabetes. Neuroendocrinology. 2023;113(8):875-884

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 37080173

    View Full Text